Capital Asset Advisory Services LLC Has $462,000 Position in Astrazeneca Plc $AZN

Capital Asset Advisory Services LLC lessened its holdings in Astrazeneca Plc (NYSE:AZN) by 56.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,303 shares of the company’s stock after selling 3,033 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Astrazeneca were worth $462,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in AZN. Bank of America Corp DE increased its position in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Astrazeneca by 2.1% during the fourth quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after purchasing an additional 438,709 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Astrazeneca by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after purchasing an additional 445,014 shares during the period. Morgan Stanley grew its stake in shares of Astrazeneca by 3.2% in the fourth quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after purchasing an additional 432,939 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after purchasing an additional 582,183 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Finally, UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Price Performance

AZN stock opened at $194.96 on Friday. The firm has a market cap of $302.36 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company’s fifty day simple moving average is $183.91 and its 200 day simple moving average is $187.76.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. On average, analysts expect that Astrazeneca Plc will post 10.28 earnings per share for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.